NCT00418379View on ClinicalTrials.gov

Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

PHASE3CompletedINTERVENTIONAL
Enrollment

633

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2011

Conditions
Allergy
Interventions
DRUG

300 IR (4M)

300 IR grass pollen allergen extract tablet starting 4 months before the pollen season

DRUG

300 IR (2M)

300 IR grass pollen allergen extract tablet starting 2 months before the pollen season

DRUG

Placebo

Placebo tablet

Trial Locations (1)

31400

DIDIER, Toulouse

Sponsors

Lead Sponsor

Stallergenes Greer
All Listed Sponsors
lead

Stallergenes Greer

INDUSTRY